目的 探討培元通腦膠囊聯(lián)合馬來(lái)酸桂哌齊特治療老年急性腦梗死的臨床療效。方法 選取天津市靜海區(qū)醫(yī)院2017年8月-2019年8月收治的老年急性腦梗死患者76例，隨機(jī)分為對(duì)照組（38例）和治療組（38例）。對(duì)照組靜脈滴注馬來(lái)酸桂哌齊特注射液，320 mg加入5%葡萄糖或生理鹽水250 mL，1次/d。治療組在對(duì)照組的基礎(chǔ)上口服藥物培元通腦膠囊，3粒/次，3次/d。兩組患者治療14 d。觀察兩組患者臨床療效，同時(shí)比較治療前后兩組患者白細(xì)胞介素-1（IL-1）、白細(xì)胞介素-6（IL-6）、腫瘤壞死因子-α（TNF-α）水平及NIHSS評(píng)分和不良反應(yīng)情況。結(jié)果 治療后，對(duì)照組和治療組臨床有效率分別為65.79%和97.37%，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組患者IL-1、IL-6、TNF-α水平均明顯降低（P<0.05），且治療組明顯低于對(duì)照組（P<0.05）。治療7、14 d，治療組患者NIHSS評(píng)分均低于對(duì)照組患者（P<0.05）。治療中，對(duì)照組不良反應(yīng)發(fā)生率為47.37%，顯著高于治療組的13.16%，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 培元通腦膠囊聯(lián)合馬來(lái)酸桂哌齊特注射液治療老年急性腦梗死效果顯著，能有效降低機(jī)體血清炎性因子水平，顯著改善腦組織細(xì)胞缺血、缺氧癥狀。

Objective To explore the curative effect of Peiyuan Tongnao Capsules combined with cinepazide maleate in treatment of senile acute cerebral infarction. Methods Patients (76 cases) with acute cerebral infarction in Jinghai Hospital of Tianjin from August 2017 to August 2019 were randomly divided into control (38 cases) and treatment (38 cases) groups. Patients in the control group were iv administered with Cinepazide Maleate Injection, 320 mg added into 5% glucose injection or normal saline 250 mL, once daily. Patients in the treatment group were po administered with Peiyuan Tongnao Capsules on the basis of the control group, 3 grains/time, three times daily. Patients in two groups were treated for 14 d. After treatment, the clinical efficacy was evaluated, and the levels of IL-1, IL-6 and TNF-α, NIHSS scores and the adverse reactions in two groups before and after treatment were compared. Results After treatment, the clinical efficacy and in the control and treatment groups was 65.79% and 97.37% respectively, and there were differences between two groups (P<0.05). After treatment, the serum levels of IL-1, IL-6 and TNF-α in two groups were significantly decreased (P<0.05), and which in the treatment group were significantly lower than those in the control group (P<0.05). After treatment for 7 and 14 d, the NIHSS scores in the treatment group were significantly lower than those in the control group (P<0.05). During the treatment, the adverse reactions rate in the control group was 47.37%, which was significantly higher than 13.16% in treatment the group, with significant difference between two groups (P<0.05). Conclusion The effect of Peiyuan Tongnao Capsules combined with cinepazide maleate in treatment of senile acute cerebral infarction is significant, can effectively reduce the level of serum inflammatory factors, and significantly improve the symptoms of cerebral ischemia and hypoxia.

R971